Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Nov 28;180(2):224–235. doi: 10.1111/bjh.15025

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 The Authors. British Journal of Haematology published by John Wiley & Sons Ltd

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Forest plots of treatment effects on median PFS by subgroups according to MIPI‐based characteristics (A), other patient characteristics (B), and prior treatment history (C). Improved PFS to the left of the vertical line (i.e., at 1) favours lenalidomide and to the right of the line favours IC. Black squares represent the HR; horizontal lines lines represent 95% CI. Statistically significant (P ≤ 0·05) values and the specified factors are shown in bold. 95% CI, 95% confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; IC, investigator's choice; Intermed., intermediate; LDH, lactate dehydrogenase; Len, l lenalidomide; MCL, mantle cell lymphoma; MIPI, MCL International Prognostic Index; PFS, progression‐free survival; SCT, stem cell transplantation; WBC, white blood cell count.